Biblio

Author Title [ Type

] Year

Filters: Author is Murphy, Philip M [Clear All Filters]

Journal Article

Anginot A, Nguyen J, Nader ZAbou, Rondeau V, Bonaud A, Kalogeraki M, Boutin A, Lemos JP, Bisio V, Koenen J, et al. WHIM Syndrome-linked CXCR4 mutations drive osteoporosis. Nat Commun. 2023;14(1):2058.

Li Z, Xu X, Weiss ID, Jacobson O, Murphy PM. Pre-treatment of Allogeneic Bone Marrow Recipients with the CXCR4 Antagonist AMD3100 Transiently Enhances Hematopoietic Chimerism without Promoting Donor-specific Skin Allograft Tolerance. Transpl Immunol. 2015.

McDermott DH, Liu Q, Velez D, Lopez L, Anaya-O'Brien S, Ulrick J, Kwatemaa N, Starling J, Fleisher TA, Priel DALong, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood. 2014.

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AHovard, Locati M, Luster AD, et al. International Union of Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors. Pharmacol Rev. 2014;66(1):1-79.

Li W, Liu C, Burns N, Hayashi J, Yoshida A, Sajja A, González-Hernández S, Gao J-L, Murphy PM, Kubota Y, et al. Alterations in the spatiotemporal expression of the chemokine receptor CXCR4 in endothelial cells cause failure of hierarchical vascular branching. Dev Biol. 2021.